Retroperitoneal Lymphadenectomy Vs. 1 Cycle BEP As Adjuvant Therapy For Non-Seminomatous Testicular Tumours In Clinical Stage I

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 11 May 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

UroToday.com - In our publication, Table 5 seems to be very important for further discussion, containing a meta-analysis of all authors (Corti Ortiz/Gilbert/Tandstad/Oliver/Westermann/Hartmann) using only 1 cycle of BEP for the treatment of clinical stage I nonseminoma.

The group without risk factors for recurrence was comprised 300 patients - of whom, 4 experienced relapses (1.33%), whereas in the group with risk factors (312 patients) 9 relapses occurred (2.88%). Altogether 612 patients had 13 relapses (2.1%). The median follow-up ranged from 47 to 118 months. All of the relapsed patients had been cured by 3 additional cycles of standard chemotherapy.

In conclusion, the data indicate that 1 cycle of BEP is able to reduce the risk of relapse from nearly 50% to 2.9% - even in high-risk patients.

Written by M. Hartmann et al., as part of Beyond the Abstract on UroToday.com

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2009 - UroToday

• Additional
• References
• Citations